Literature DB >> 21181929

Epstein-barr virus in diffuse large B-Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries.

Naoki Wada1, Junichiro Ikeda, Yumiko Hori, Shigeki Fujita, Hiroyasu Ogawa, Toshihiro Soma, Haruo Sugiyama, Shirou Fukuhara, Akihisa Kanamaru, Masayuki Hino, Yuzuru Kanakura, Eiichi Morii, Katsuyuki Aozasa.   

Abstract

According to previous reports, the frequency of Epstein-Barr virus (EBV) positivity in diffuse large B-cell lymphoma is higher in East Asia (approximately 9%) than in Western countries. The presence of the EBV genome was examined in diffuse large B-cell lymphoma patients registered with the Osaka Lymphoma Study Group (OLSG) in Osaka, Japan, situated in East Asia. The EBV-positive rate was examined with in situ hybridization (ISH) in 484 immunocompetent diffuse large B-cell lymphoma patients registered with OLSG. The male-to-female ratio was 1.29, with ages ranging from 16 to 95 (median, 68) years. ISH with EBV-encoded small RNAs (EBER) probes revealed positive signals in the nuclei of tumor cells: the frequency of positively stained cells among all tumor cells was almost none in 458 cases, 5-10% in 5, 10-20% in 5, 20-50% in 11, and >50% in 5. When the frequency was >20% or >50%, the EBV-positive rate in the present series (3.3% or 1.0%) was rather similar to that reported in Western cases. Careful evaluation of patient backgrounds, including age distribution, type of lymphomas, exclusion of immunocompromised patients, and establishment of definite criteria for EBV positivity (>20%, >50%, or almost all tumor cells) are essential in comparing geographical differences. 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21181929     DOI: 10.1002/jmv.21967

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  13 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.

Authors:  Alina Nicolae; Stefania Pittaluga; Shahed Abdullah; Seth M Steinberg; Thu Anh Pham; Theresa Davies-Hill; Liqiang Xi; Mark Raffeld; Elaine S Jaffe
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

3.  ID1 upregulation and FoxO3a downregulation by Epstein-Barr virus-encoded LMP1 in Hodgkin's lymphoma.

Authors:  Jun-Ichiro Ikeda; Naoki Wada; Satoshi Nojima; Shinichiro Tahara; Yoko Tsuruta; Kaori Oya; Eiichi Morii
Journal:  Mol Clin Oncol       Date:  2016-09-08

4.  Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Authors:  Chi Young Ok; Ling Li; Zijun Y Xu-Monette; Carlo Visco; Alexander Tzankov; Ganiraju C Manyam; Santiago Montes-Moreno; Karen Dybkaer; Karen Dybaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Jiayu Chen; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; John P Farnen; Michael B Møller; Carlo E Bueso-Ramos; Roberto N Miranda; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 5.  EBV-positive diffuse large B-cell lymphoma of the elderly.

Authors:  Chi Young Ok; Thomas G Papathomas; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-05-06       Impact factor: 22.113

6.  Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.

Authors:  Ting-Xun Lu; Jin-Hua Liang; Yi Miao; Lei Fan; Li Wang; Xiao-Yan Qu; Lei Cao; Qi-Xing Gong; Zhen Wang; Zhi-Hong Zhang; Wei Xu; Jian-Yong Li
Journal:  Sci Rep       Date:  2015-07-23       Impact factor: 4.379

7.  A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly.

Authors:  Tathiana Azevedo de Andrade; Adriane Feijo Evangelista; Antonio Hugo Froes Campos; Wagner Augusto Poles; Natalia Morais Borges; Claudia Malheiros Coutinho Camillo; Fernando Augusto Soares; Jose Vassallo; Roberto Pinto Paes; Maria Claudia Zerbini; Cristovam Scapulatempo; Antonio Correa Alves; Ken H Young; Gisele Wally Braga Colleoni
Journal:  Oncotarget       Date:  2014-12-15

8.  Epstein-Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland.

Authors:  Mateusz Ziarkiewicz; Dominika Wołosz; Tomasz Dzieciątkowski; Ewa Wilczek; Jadwiga Dwilewicz-Trojaczek; Wiesław Wiktor Jędrzejczak; Beata Gierej; Bogna Ziarkiewicz-Wróblewska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-06-18       Impact factor: 4.291

9.  Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression.

Authors:  Sean I Tracy; Thomas M Habermann; Andrew L Feldman; Matthew J Maurer; Ahmet Dogan; Usha S Perepu; Sergei Syrbu; Stephen M Ansell; Carrie A Thompson; George J Weiner; Grzegorz S Nowakowski; Cristine Allmer; Susan L Slager; Thomas E Witzig; James R Cerhan; Brian K Link
Journal:  Haematologica       Date:  2017-11-23       Impact factor: 9.941

10.  Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis.

Authors:  Xiaojuan Gao; Jia Li; Yaqi Wang; Shuai Liu; Baohong Yue
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.